Diversifying its range of cancer diagnostic products, Exact Sciences has agreed to acquire Genomic Health in a cash and stock deal valued at US$2.8 B. Exact shareholders are expected to own approximately 91% of the combined company while Genomic stockholders are expected to own the remaining 9%. The new company will be led by Exact’s Cologuard, a colorectal cancer diagnosis test, and Genomic’s Oncotype DX, a suite of screening tests for breast, colon and prostate cancer.